Marsh & McLennan Companies (MRSH) is piloting Project Leapfrog, an AI powered risk strategy tool that gives select clients real time guidance on corporate risk and puts the stock’s insurance analytics capabilities in sharper focus for investors.

The share price has come under pressure recently, with a 30 day share price return down 8.3% and year to date share price return down 12.79%, while the 1 year total shareholder return has declined 27.11%. This suggests current news on Project Leapfrog is emerging against a backdrop of fading momentum after a stronger 5 year total shareholder return of 27.91%.

If Project Leapfrog has put AI driven risk tools on your radar, it could be worth broadening your search and checking out 61 profitable AI stocks that aren't just burning cash

With Marsh & McLennan shares under pressure despite positive reported revenue and net income growth and a discount to analyst targets and intrinsic estimates, is the pullback hinting at value, or is the market already pricing in future growth?

Most Popular Narrative: 21.6% Undervalued

With Marsh & McLennan trading at $159.14 against a widely followed fair value estimate of $203.10, the current pullback sits in clear tension with that narrative.

Strategic investments in digital transformation, advanced analytics, and AI (for example, proprietary data tools for risk modeling and agentic interfaces) are expected to enhance operational efficiency and improve product and service offerings, enabling margin expansion and net earnings growth through improved client retention and lower cost to serve.

If you want to see what sits behind that fair value, focus on how steady revenue growth, wider margins and a richer earnings multiple all tie together.

Result: Fair Value of $203.10 (UNDERVALUED)

However, that undervalued story could unravel if AI driven disruption erodes Marsh & McLennan's brokerage economics or if large acquisitions fail to deliver the expected efficiencies.

Another View: Earnings Multiple Sends a Different Signal

That 21.6% DCF style undervaluation story sits uncomfortably next to the current earnings multiple. Marsh & McLennan trades on a P/E of 19.5x, which is slightly above peers at 19.3x and well above the US insurance industry at 11.1x. The fair ratio is 13.5x, which implies less margin for error if growth or margins fall short.

Next Steps

With mixed signals on value and AI potential running through this story, it makes sense to look at the data directly and move quickly to form your own view, starting with the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If this Marsh & McLennan story has sharpened your thinking, do not stop here. Broaden your watchlist with focused screens that surface very different types of opportunities.

• Target potential mispricings by scanning for quality companies trading below what the market might be implying with the 46 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies in the 13 dividend fortresses that currently offer higher yields with an emphasis on stability.
• Prioritise resilience by hunting for companies flagged in the 69 resilient stocks with low risk scores that pair lower risk scores with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.